GeoVax Sponsors 2025 Dr. David Satcher Global Health Equity Summit to Advance Vaccine Access

GeoVax, Inc., a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced its sponsorship of the 3rd Annual Dr. David Satcher Global Health Equity Summit hosted by Morehouse School of Medicine. The summit, taking place October 2, 2025, at Morehouse School of Medicine in Atlanta, Georgia, convenes global health experts, policymakers, researchers, community organizations, and students to address pressing challenges in health equity.

The summit's theme, "The Quest for Health Equity & Justice: A Glocal Perspective," highlights how local innovations, policies, and partnerships can be scaled globally to close equity gaps in healthcare access. This year's event features keynote speaker Dr. John N. Nkengasong, U.S. Global AIDS Coordinator and Senior Bureau Official for Global Health Security and Diplomacy, alongside distinguished leaders across academic, government, and private sectors. Sessions will explore critical topics including vaccine access and trust, innovations in pandemic preparedness, and community-driven models for health equity.

Representing GeoVax at the summit will be Mary Hauser, PhD, Director of Preclinical Research, who will be available throughout the event to discuss the company's vaccine and immunotherapy programs. Dr. Hauser will highlight GeoVax's work advancing MVA-based vaccines designed specifically to meet the needs of immunocompromised and underserved populations, underscoring the company's commitment to ensuring scientific innovation translates into real-world accessibility for those most in need.

David Dodd, Chairman & CEO of GeoVax, emphasized the importance of this commitment, stating, "Health equity is not just a goal - it is a mandate for global progress. We are honored to support the Satcher Summit and partner with Morehouse School of Medicine in advancing solutions that ensure lifesaving vaccines and therapies reach those most in need." This sponsorship aligns with GeoVax's broader mission to develop vaccines that address critical gaps in global health protection.

GeoVax's lead clinical program, GEO-CM04S1, represents a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. The vaccine is being evaluated as a primary vaccine for immunocompromised patients, including those with hematologic cancers and other populations for whom current authorized COVID-19 vaccines are insufficient. Additional trials are examining its effectiveness as a booster vaccine in patients with chronic lymphocytic leukemia and as a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines.

The company's oncology program includes Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation. For more information about the current status of clinical trials and other updates, visit https://www.geovax.com.

The Dr. David Satcher Global Health Equity Summit, founded in honor of Dr. David Satcher, the 16th Surgeon General of the United States and Founding Director of the Satcher Health Leadership Institute, provides a platform for advancing health equity through research, innovation, and policy. Now in its third year, the event serves as a catalyst for collaboration and action to achieve sustainable change in global and community health. GeoVax's participation in this important forum demonstrates the biotechnology industry's growing recognition that equitable access to medical innovations is essential for meaningful public health impact worldwide.